Background: Coagulase-negative staphylococci (CoNS) represent one of the major resistant nosocomial pathogens where its biofilmrelated infections often fail to respond to antibiotic chemotherapy. Here, we studied the resistance profiles and biofilm formation in CoNS isolates from clinical specimens at Al Shifa hospital in Gaza, Palestine. Methods:This study was carried out from March to July 2013 and included 81 clinical isolates. Identification and antibiotic susceptibility testing were performed using VITEK-2 system. The presence of nuc and mecA genes was performed using multiplex PCR. Qualitative and quantitative biofilm assays were performed using standard methods. Results:Of the 81 clinical CoNS isolates, S. haemolyticus was the most common species (34, 42%), followed by S. epidermidis (26, 32.1%) and S. saprophyticus (13, 16%). The majority of isolates (83.9%) were from surgery, ICUs, pediatrics and medicine wards and the most common source was pus (28, 34.6%). Antibiotic resistance was highest against aminoglycosides, β-lactams, carbapenems, cephalosporins, fluoroquinolones, fosfomycin and macrolides. Though, no resistance was detected against rifampicin, vancomycin, teicoplanin, nitrofurantoin, linezolid and mupirocin. The antibiotic resistance among MR-CoNS was significantly higher than that among MS-CoNS. Nearly 88.9% of isolates were multidrug resistant with higher percentage among MRCoNS. Most S. epidermidis (76.9%) isolates were biofilm producer, with statistically significant association between methicillin resistance and biofilm production. IntroductionCoagulase-negative staphylococci (CoNS) are now representing one of the major nosocomial pathogens and among the most frequently isolated bacteria in the clinical microbiology laboratories [1][2][3][4][5]. They are responsible for bacteremia, endocarditis, mediastinitis, meningitis and progressive joint destruction mainly in patients with neutropenia, indwelling foreign devices, intravascular catheters or other foreign bodies [1,3,4]. The clinical most relevant CoNS are Staphylococcus epidermidis, S. lugdunensis, S. saprophyticus , and S. capitis [6,7].Biofilm production by CoNS, specially S. epidermidis , is considered as an important factor in the pathogenesis of implanted medical devices associated infections [1,2,8,9]. Biofilm formation takes place in four successive phases: the attachment of the bacteria to biotic or abiotic surface; the proliferation and accumulation of bacteria in multilayered cell clusters; the growth of biofilm into a thick and structured layer, and finally the detachment and circulation of single cells or cell agglomerates via the bloodstream [1,2].Many literature surveys revealed that CoNS showed high resistance against most of the commonly used therapeutic antibacterial agents including methicillin. Irrespective of geographical locations, a worldwide SENTRY study showed that, about 70-75% of CoNS are resistant to methicillin [10]. There is a significant increase in the methicillin-resistant coagulase negative st...
In this research CaO-Ag-NPs @CaCO 3 nanocomposite was prepared by treatment of calcined calcium oxalate [CaO, Ca(OH) 2 and CaCO 3 ] with sol of silver nanoparticles (Ag-NPs). Several techniques were used to investigate the structural properties of CaO-Ag-NPs@CaCO 3 nanocomposite including FTIR, UV/VIS, XRD, TEM and TGA. XRD and TEM and UV/VIS results showed that silver nanoparticles incorporated with calcium oxide (CaO-Ag-NPs) are incorporated with calcium carbonate (CaO-Ag-NPs@CaCO 3). It is confirmed that the CaO-Ag-NPs @CaCO 3 nanocomposite showed strong antimicrobial activity against Escherichia coli, and Staphylococcus aurous.
Objectives: The present study was designed to screen the antibacterial and synergistic effects of Allium sativum, Ecballiumelaterium, Pelargoniumgraveolens, Rosmarinusofficinalis, Phagnalonrupestre and Rutagraveolens plant extracts and essential oils against the followingclinical multidrug-resistant(MDR) Gram negative pathogenic isolates: Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. Methods: All extracts and essential oils were screened for their antibacterial activity and synergistic effect in combination with known antibiotics.The minimum inhibitory concentrations (MICs) and the minimum bactericidal concentrations (MBCs) of the plant extracts were assessed. Results: Our results revealed that, the average diameter of inhibition zones ranged from: 7-14 mm, 7-17 mm, 8-17 mm and 7-13 mm for water, ethanol, methanol and EOs extracts, respectively. The MICs and MBCs were determined for extracts which showed antibacterial activity. The average MICs values ranged from 1.6-100 mg/ml, 1.6-50 mg/ml, 0.39 -50 mg/ml and 3.13-100 μl/ml for water, ethanol, methanol and EOs extracts, respectively. While MBCs values ranged from 25->200 mg/ml, 25- 200 mg/ml and 50->200 μl/ml for water, ethanol, methanol and EOs extracts, respectively. The antibacterial activity of the afore mentioned plant extracts combined with Ciprofloxacin (CIP), Ampicillin (AM), Cefotaxime (CTX), Nalidixic acid (NA), Norofloxacin (NOR), Cefuroxime (CXM), Cefaclor (CF), Ofloxacin (OFX), Cefalexin (CL), Tetracycline (TE), Rifampicin (RIF), Amoxyclav (AMC) and Amikacin (AK) had different degrees of synergism against the selectedbacteria.Essential oils (Eos) of screened plants had the best synergism with antibiotics than the plant extracts against the tested bacteria. The best synergism was noticed in the Eos of A. sativum, P. graveolens and R. officinalis. Conclusion: It was concluded that the synergistic effect of antibiotics and plant extracts is promising approach fortreating infectious diseases caused byMDR Gram negative bacteria. Bangladesh Journal of Medical Science Vol.19(3) 2020 p.509-519
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.